Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD32b defines distinct dendritic cell lineages generated from the culture of bone marrow with GM-CSF.

Frontiers in immunology·2026
Same author

Uncertainty of Fit - Serving People with Borderline Personality Disorder on an Assertive Community Treatment Team Setting: Experiences and Perspectives of Clinicians from a Flexible ACT Team.

Community mental health journal·2026
Same author

Viral vector-mediated SLC9A6 gene replacement reduces cerebellar motor and molecular abnormalities in the shaker rat model of Christianson syndrome.

Human molecular genetics·2026
Same author

Unequal access to timely care: Geographic variation in prehospital time among injured patients at risk of hemorrhagic shock.

Transfusion·2026
Same author

Prehospital blood transfusion coalition core competencies for emergency medical services personnel.

Trauma surgery & acute care open·2026
Same author

Predictive Validity of the TIGER Score for Daily-Life Disease Burden, Complications, and Medication Use in Inflammatory Bowel Disease After 12 Months.

Clinical and translational gastroenterology·2025
Same journal

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.1K

Aptamer-targeted antigen delivery.

Brian C Wengerter1, Joseph A Katakowski2, Jacob M Rosenberg3

  • 1Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 1, 2014
PubMed
Summary
This summary is machine-generated.

Nucleic acid aptamers targeting DEC205 efficiently deliver antigens to dendritic cells, enhancing CD8 T cell responses. This aptamer-based approach shows promise for developing effective T cell-mediated vaccines against tumors.

More Related Videos

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

1.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

7.4K

Related Experiment Videos

Last Updated: May 1, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.1K
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
03:38

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction

Published on: October 6, 2022

1.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

7.4K

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • T cell-mediated immunity, particularly CD8 T cell responses, is crucial for effective therapeutic vaccines.
  • Targeting antigens to professional antigen-presenting cells enhances vaccine efficacy.
  • Nucleic acid aptamers offer a novel alternative to protein-based targeting strategies.

Purpose of the Study:

  • To develop and evaluate aptamers targeting the murine DEC205 receptor for enhanced antigen delivery and T cell activation.
  • To investigate the potential of aptamer-mediated antigen delivery for therapeutic vaccine development.

Main Methods:

  • Selection of aptamers that specifically bind to the murine DEC205 receptor.
  • Conjugation of a minimized aptamer to the model antigen ovalbumin (OVA).
  • In vitro and in vivo assessment of antigen crosspresentation, T cell proliferation, and cytokine production (IFN-γ, IL-2).
  • Evaluation of tumor growth inhibition in a B16 tumor model.

Main Results:

  • DEC205-targeted aptamer-OVA conjugates facilitated antigen crosspresentation.
  • Significant proliferation and cytokine production (IFN-γ, IL-2) by CD8 T cells were observed.
  • Aptamer-OVA conjugates demonstrated efficacy in inhibiting the growth of established OVA-expressing B16 tumors.
  • Enhanced immune responses compared to a nonspecific RNA control.

Conclusions:

  • Aptamer technology can be effectively utilized for targeted antigen delivery to CD8α(+) dendritic cells via DEC205.
  • DEC205-targeted aptamer-antigen conjugates stimulate robust CD8 T cell responses, leading to anti-tumor effects.
  • This approach represents a promising new strategy for the development of T cell-mediated vaccines.